Otsuka Holdings Co., Ltd. (OTSKF)
OTCMKTS · Delayed Price · Currency is USD
58.42
0.00 (0.00%)
Dec 2, 2025, 9:30 AM EST
Otsuka Holdings Revenue
Otsuka Holdings had revenue of 637.98B JPY in the quarter ending September 30, 2025, with 2.71% growth. This brings the company's revenue in the last twelve months to 2.42T, up 6.56% year-over-year. In the year 2024, Otsuka Holdings had annual revenue of 2.33T with 15.42% growth.
Revenue (ttm)
2.42T JPY
Revenue Growth
+6.56%
P/S Ratio
1.95
Revenue / Employee
68.44M JPY
Employees
35,338
Market Cap
31.85B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.33T | 311.29B | 15.42% |
| Dec 31, 2023 | 2.02T | 280.57B | 16.14% |
| Dec 31, 2022 | 1.74T | 239.72B | 16.00% |
| Dec 31, 2021 | 1.50T | 75.45B | 5.30% |
| Dec 31, 2020 | 1.42T | 26.59B | 1.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
Otsuka Holdings News
- 9 days ago - US FDA approves Otsuka's kidney disease drug - Reuters
- 9 days ago - Otsuka Pharma Submits NDA For Centanafadine In ADHD - Nasdaq
- 4 weeks ago - Otsuka 9-month Profit Rises; Revenue Up 5.1% - Nasdaq
- 7 weeks ago - Taiho Pharma, Haihe Biopharma Enter Into Agreement For Ovarian Cancer Drug Candidate Risovalisib - Nasdaq
- 2 months ago - Shares of Asian drugmakers drop after Trump threatens tariffs - Reuters
- 4 months ago - Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Otsuka Holdings Co., Ltd. (OTSKY) Q2 FY2024 Earnings Call Transcript - Seeking Alpha